These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 36168632)

  • 21. Transcytosis-enabled active extravasation of tumor nanomedicine.
    Zhou Q; Li J; Xiang J; Shao S; Zhou Z; Tang J; Shen Y
    Adv Drug Deliv Rev; 2022 Oct; 189():114480. PubMed ID: 35952830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
    Frazier N; Ghandehari H
    Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulating angiogenesis with integrin-targeted nanomedicines.
    Duro-Castano A; Gallon E; Decker C; Vicent MJ
    Adv Drug Deliv Rev; 2017 Sep; 119():101-119. PubMed ID: 28502767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer nanomedicines harnessing tumor microenvironmental components.
    Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
    Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
    Gu W; Meng F; Haag R; Zhong Z
    J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials.
    Eskandari Z; Bahadori F; Celik B; Onyuksel H
    J Pharm Pharm Sci; 2020; 23(1):132-157. PubMed ID: 32369437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment.
    Huang X; Mu N; Ding Y; Lam HW; Yue L; Gao C; Chen T; Yuan Z; Wang R
    Acta Biomater; 2022 Jul; 147():356-365. PubMed ID: 35577046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques.
    Pegoraro C; Domingo-Ortí I; Conejos-Sánchez I; Vicent MJ
    Adv Drug Deliv Rev; 2024 Apr; 207():115195. PubMed ID: 38325562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.